Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
Conditions
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
- Recurrent Ovarian Carcinoma
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer
Interventions
- DRUG: Cyclophosphamide
- PROCEDURE: Laboratory Biomarker Analysis
- BIOLOGICAL: Oregovomab
Sponsor
Gynecologic Oncology Group
Collaborators